FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 722 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR First treatment approved in England for advanced bile duct cancer July 22, 2021 EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... August 5, 2021 Load more HOT NEWS ΠΟΝΟΣ Breast Cancer Survivor’s Family Designs a Holiday Light Show in Her... ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in... Melanoma Cells Are More Likely to Spread after a Stopover in...
